MedWatch

Lundbeck sells preclinical drugs to former research exec

The focus on four psychiatric disorders has made Lundbeck sell off two preclinical research projects to a US-based company founded by the former Vice President of the company's US research department. Lundbeck may still profit from the drugs, as there is an option for milestones and royalties.

Two drugs originally developed as possible treatments for psychiatric disorders no longer fit with Lundbeck's business plan, and have therefore been sold. Photo: Lundbeck

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Immunterapi fra Roche øger overlevelsen hos patienter med brystkræft

Immunterapien Tecentriq fra Roche har for første gang nogensinde kunnet fremvise effekt i behandlingen af patienter med såkaldt triple-negativ brystkræft. De nye studieresultater giver et fingerpeg om immunterapiens mulige potentiale som en forebyggende behandling til patienter med tidlig brystkræft, vurderer overlæge.

Lundbeck vil slå konkurrenter med data om seksuel sundhed

Med accept fra de amerikanske lægemiddelmyndigheder må Lundbeck nu benytte sin antidepressiv Trintellix’ positive effekter på seksuel sundhed i markedsføringen, og det kan give en god konkurrencefordel, mener forskningsdirektør.

Related articles